Cholesteryl ester transfer protein inhibitory oxoacetamido-benzamide derivatives
Glide docking, pharmacophore mapping, and synthesis
DOI:
https://doi.org/10.1590/s2175-97902022e20028Keywords:
CETP Inhibitors, Cholesteryl ester transfer protein, Dyslipidemia, Glide docking, Oxoacetamido-benzamides, Pharmacophoric featuresAbstract
Dyslipidemia is an abnormal lipid profile associated with many common diseases, including coronary heart disease and atherosclerosis. Cholesteryl ester transfer protein (CETP) is a hydrophobic plasma glycoprotein that is responsible for the transfer of cholesteryl ester from high-density lipoprotein athero-protective particles to pro-atherogenic very low-density lipoprotein and low-density lipoprotein particles. The requirement for new CETP inhibitors, which block this process has driven our current work. Here, the synthesis as well as the ligand-based and structure-based design of seven oxoacetamido-benzamides 9a-g with CETP inhibitory activity is described. An in vitro study demonstrated that most of these compounds have appreciable CETP inhibitory activity. Compound 9g showed the highest inhibitory activity against CETP with an IC50 of 0.96 μM. Glide docking data for compounds 9a-g and torcetrapib provide evidence that they are accommodated in the CETP active site where hydrophobic interactions drive ligand/CETP complex formation. Furthermore, compounds 9a-g match the features of known CETP active inhibitors, providing a rationale for their high docking scores against the CETP binding domain. Therefore, these oxoacetamido-benzamides show potential for use as novel CETP inhibitors.
Downloads
References
Abu Khalaf R, Abd El-Aziz H, Sabbah D, Albadawi G, Abu Sheikha G. CETP inhibitory activity of chlorobenzyl benzamides: QPLD docking, pharmacophore mapping, and synthesis. Lett Drug Des Discov. 2017a;14(12):1391-400.
Abu Khalaf R, Abu Sheikha G, Al-Sha’er M, Albadawi G, Taha M. Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors. Med Chem Res. 2012;21(11):3669-80.
Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Eur J Med Chem. 2010;45(4):1598-617.
Abu Khalaf R, Al-Rawashdeh S, Sabbah D, Abu Sheikha G. Molecular docking and pharmacophore modeling studies of fluorinated benzamides as potential CETP Inhibitors. Med Chem. 2017b;13(3):239-53.
Abu Khalaf R, Sabbah D, Al-Shalabi E, Bishtawi S, Albadawi G, Abu Sheikha G. Synthesis, biological evaluation, and molecular modeling study of substituted benzyl benzamides as CETP inhibitors. Arch Pharm. 2017c;350(12):e1700204.
Abu Sheikha G, Abu Khalaf R, Melhem A, Albadawi G. Design, synthesis, and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors. Molecules. 2010;15(8):5721-33.
Chirasani VR, Revanasiddappa PD, Senapati S. Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity. J Biol Chem. 2016;291(37):19462-73.
Clark MA, Finkel R, Rey JA, Whalen K. Lippincott’s illustrated reviews. Pharmacology, 5th ed.; MD: Wolters Kluwer Health/ Lippincott Williams & Wilkins: Baltimore, 2012.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem . 2004;47(7):1739-49.
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren Ta, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem . 2006;49(21):6177-96.
Gurr MI, Harwood JL, Frayn KN. Lipid Biochemistry: An Introduction, 5th ed.; Wiley-Blackwell, 2008.
Liu S, Mistry A, Reynolds JM, Lloyd DB, Griffor MC, Perry DA, et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem . 2012;287(44):37321-9.
Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR et al. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis.2016, No. 141, Report No.: 14-05204-EF-2, Rockville (MD): Agency for Healthcare Research and Quality (US).
Mezdour H, Kora I, Parra HJ, Tartar A, Marcel YL, Fruchart JC. Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies. Clin Chem. 1994;40(4):593-7.
Mullard A. CETP inhibitors stumble on. Nat Rev Drug Discov. 2017;16(10):669.
Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195-211.
Patel JP, Brocks DR. Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. Br J Pharmacol. 2010;161(6):1427-40.
Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, Garcia-Rios A, Tsai MY, Delgado-Lista J et al. Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. J Clin Lipidol. 2016;10(5):1163-71.
Protein Preparation Wizard, Maestro, Macromodel, QPLD-dock, and Pymol. Schrödinger, LLC, Portland, OR, U.S.A., 2016.
Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJP, Kuivenhoven JA, Zwinderman AH, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29(22):2792-9.
Sarzynski MA, Schuna JM, Carnethon MR, Jacobs DR, Lewis CE, Quesenberry CP, et al. Association of fitness with incident dyslipidemias over 25 years in the coronary artery risk development in young adults study. Am J Prev Med. 2015;49(5):745-52.
Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:1-9.
Suhy A, Hartmann K, Newman L, Papp A, Toneff T, Hook V, et al. Genetic variants affecting alternative splicing of human cholesteryl ester transfer protein. Biochem Biophys Res Commun. 2014;443(4):1270-4.
The Molecular Operating Environment, Chemical Computing Group, Inc Montreal, Quebec, Canada, 2016.
Yassine HN, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism. 2014;63(5):727-34.
Zhang X, Zhang Y, Liu Y, Wang J, Xu Q, Yu X, et al. Medium- chain triglycerides promote macrophage reverse cholesterol transport and improve atherosclerosis in ApoE-deficient mice fed a high-fat diet. Nutr Res. 2016;36(9):964-73.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
